Jun 10 |
ChromaDex (CDXC) Up as Ataxia Candidate Gets Orphan Drug Tag
|
Jun 7 |
ChromaDex shares jump 9% on FDA designations for NRC
|
Jun 7 |
ChromaDex Receives Exclusive U.S. FDA Orphan Drug Designation (ODD) and Rare Pediatric (RPD) Disease Designation for Nicotinamide Riboside Chloride (NRC) for the Treatment of Ataxia Telangiectasia (AT)
|
Jun 4 |
ChromaDex to Participate in Renmarkâs Virtual Non-Deal Roadshow on Tuesday, June 11, 2024
|
Jun 2 |
ChromaDex (NASDAQ:CDXC) shareholders are still up 82% over 1 year despite pulling back 12% in the past week
|
May 10 |
ChromaDex Corp (CDXC) Q1 2024 Earnings: Aligns with EPS Projections, Misses Revenue Estimates
|
May 9 |
ChromaDex Corporation (NASDAQ:CDXC) Q1 2024 Earnings Call Transcript
|
May 9 |
Q1 2024 Chromadex Corp Earnings Call
|
May 9 |
ChromaDex Corp (CDXC) Q1 2024 Earnings Call Transcript Highlights: Navigating Challenges and ...
|
May 9 |
ChromaDex Corporation (CDXC) Q1 2024 Earnings Call Transcript
|